Recent developments in ocular drug delivery

Chen, Hongming

doi:10.3109/1061186x.2015.1052073

Cited by 60 publications

(38 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…), tears and blood-ocular barriers (blood aqueous and blood-retinal barriers) represent the protective barriers restricting the entry of drugs to the target sites such as the ciliary body, retina, and choroid. [129,[133][134][135][136] For example, eye drops that account for 90% of currently available ophthalmic formulations suffer very low intraocular bioavailability of around 5% owing to rapid dilution by tears and require frequent administration.…”

Section: Ocular Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Microfabricated Drug Delivery Devices: Design, Fabrication, and Applications

Zhang

Jackson

Chiao

2017

Adv Funct Materials

View full text Add to dashboard Cite

Microfabrication technology has enabled the development of novel controlled-release devices that possess an integration of structural, mechanical, and perhaps electronic features, which may address challenges associated with conventional delivery systems. In this feature article, microfabricated devices are described in terms of materials, mechanical design, working principles, and fabrication methods, all of which are key features for production of multifunctional, highly effective drug delivery systems. In addition, the current status and future prospects of different types of microfabricated devices for controlled drug delivery are summarized and analyzed with an emphasis on various routes of administration including ocular, oral, transdermal, and implantable systems. It is likely that microfabrication technology will continue to offer new, alternative solutions to design advanced and sophisticated drug delivery devices that promise to significantly improve medical care.

show abstract

Section: Ocular Deliverymentioning

confidence: 99%

“…[130] Because of the limitations associated with the current methods of ocular drug delivery, attention has turned to developing novel therapeutic strategies and new systems such as microfabricated devices for high drug delivery efficiency. [129,[133][134][135][136]…”

Section: Ocular Deliverymentioning

confidence: 99%

Microfabricated Drug Delivery Devices: Design, Fabrication, and Applications

Zhang

Jackson

Chiao

2017

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…8 Initially developed for the treatment of dry eye, 9 punctum plugs have more recently demonstrated promise as intracanalicular depots, providing sustained drug delivery to the eye. 10 A dexamethasone-eluting depot called OTX-DP (DEXTENZA™; Ocular Therapeutix, Bedford, MA) has been developed and is currently under New Drug Application review with the US Food and Drug Administration (FDA) for the treatment of postoperative ocular pain, as well as in phase 3 clinical trials for the treatment of postoperative ocular inflammation and allergic conjunctivitis.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs

Blizzard¹,

Desai²,

Driscoll³

2016

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Purpose: To examine the pharmacokinetic characteristics of sustained-release dexamethasone depots in two separate canine studies.Methods: Dexamethasone depots loaded with a clinically representative (0.4 mg) dose (DEXTENZA™; Ocular Therapeutix) or an elevated (0.7 mg) dose were inserted into the canaliculi of beagle eyes (n = 37 and n = 34, respectively). Tear fluid was collected for pharmacokinetic analysis of dexamethasone in both studies at predetermined time points. Explanted 0.4 mg depots were collected weekly to measure remaining drug level. Clinical observations and ophthalmic examinations were performed in both studies at each visit.Results: The 0.4 mg depots released a median 308 μg by day 15 and tapered to complete drug release by day 28. Median dexamethasone tear fluid concentrations in the 0.4 mg study group decreased from 2,805 ng/mL at day 7 to 0 ng/mL on day 28. Median dexamethasone tear fluid concentrations in the 0.7 mg study group decreased from 4,370 ng/mL at 6 h post insertion to 830 ng/mL on day 35. Mean ± standard deviation intraocular pressures in the 0.4 and 0.7 mg study groups were 20.7 ± 2.8 and 19.0 ± 4.1 mmHg at baseline, respectively, and demonstrated no meaningful change (20.5 ± 3.0 and 20.6 ± 2.9 mmHg, respectively) over the studies' durations. No ocular toxicities were attributed to the dexamethasone depot.Conclusion: Sustained-release dexamethasone produced no identifiable ocular toxicity in this animal model, and pharmacokinetics demonstrated a sustained and tapered drug release over 28 days at a 0.4 mg dose and exceeded 35 days at a 0.7 mg dose.

show abstract

“…A possible alternative for a long-term drug delivery is the use of contact lenses, in such a way, ocular bioavailability will be improved considering reduced tear mixing between the lens and the cornea besides the extended drug release [26]. The traditional method is to soak the lens in drug solution in order for the drug to be absorbed into the polymeric lenses, this way permits limited and slow release of the drugs into the post-lens lacrimal fluid [18,27].…”

Section: Short Commentarymentioning

confidence: 99%